Having validated our cellular model for endogenous LRRK2 expression, we then developed a protocol for overexpressing human WT and G2019S LRRK2 in LUHMES DA-like neurons, with the aim of creating a biologically relevant, but also a rapid, scalable and cost-efficient model of PD in these cells. The gene discussed is LRRK2; the disease is Parkinson disease.